Skip to main content
DOCS logo

DOCS · Doximity, Inc.

Track DOCS — free
$32.91 -0.43 (-1.29%)
Market Cap
$5.95B
Shares
178.41M
Volume · Nov 16 606.74K Avg daily vol (3M) 2.84M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$33.34 Open$33.51 Day$32.79–33.71 52W close$18.01–51.53 Avg vol 30d2.8M Short int6.9M · 3.9% of shares · 2.7d Short vol50% Last earningsNov 5, 2026 DataJun 2021–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 4, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 5
Earnings call
Revenue outlook raised as AI Search gains traction

Doximity reported Q2 revenue of $174.5 million, up 4% year-on-year, raised FY27 revenue guidance to $678 to $683 million, and said AI Search became an eight-figure bookings product, with 16 of the top 20 pharma companies purchasing programs.

4 source passages
Q2 revenue of $174.5 million outperformed our guidance with 4% year-over-year growth. For FY27, we've raised our revenue guidance range to $678 to $683 million, also representing 6% growth at the midpoint. AI Search is now an eight-figure bookings product To date, we've seen early broad-based adoption with 16 of the top 20 pharma companies having purchased programs, and three more are in our pipeline. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2027 Q2, ended Sep 30
Revenue grew 4% while gross margin fell 5 percentage points

Doximity reported revenue of $174.5 million for the three months ended September 30, 2026, up 4% from $168.5 million. Net income fell to $34.7 million from $62.1 million, while gross margin decreased 5 percentage points due to increased costs supporting AI initiatives.

Revenue $174.54M ▲ 3.6% Net income $34.73M ▼ 44.0% Diluted EPS $0.18 ▼ 41.9%
Read from the MD&A section
4 source passages
This guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues. For the three months ended September 30, 2026 and 2025, we recognized revenue of $174.5 million and $168.5 million, respectively, representing a year-over-year growth rate of 4%. For the three months ended September 30, 2026 and 2025, our net income was $34.7 million and $62.1 million and our adjusted EBITDA was $88.9 million and $100.8 million, respectively. Gross margin for the three and six months ended September 30, 2026 decreased 5 percentage points as compared to the same period in 2025, primarily due to the increased cost of revenue incurred to support our AI initiatives. Open the document at this passage
Nov 5
Current report 8-K
Revenue rises 4% as net income falls

Doximity reported fiscal 2027 second-quarter revenue of $174.5 million, up 4% year-over-year, while net income fell to $34.7 million. It expects fiscal 2027 revenue of $678 million to $683 million.

Financial results
5 source passages
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, 2026. Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year. Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%. Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows: Revenue between $678 million and $683 million. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$661.58M
Trailing 12 months
Net income (TTM)
$139.72M
Trailing 12 months
Revenue growth YoY
+3.6%
Year over year
Operating margin
26.3%
Trailing 12 months
P / E (TTM)
47.0
Trailing earnings · reciprocal yield 2.1%
FCF yield
—
TTM · current market cap
Return on invested capital
16.8%
Trailing 12 months
Net cash
$218.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-6.4%
Year over year · fewer shares
Price change (1Y)
-32.9%
Trailing year
Short interest
3.9%
Latest settlement · 2.7 days to cover
View all 125 metrics

AI Brief

Q2 FY27 earnings call · Nov 5, 2026
Q2 FY27

TL;DR. Doximity raised FY27 revenue guidance, reported broad AI Search adoption and strong workflow growth, improved AI infrastructure efficiency, maintained substantial liquidity and cash generation, and received positive early reaction to its UpToDate partnership. The quarter nevertheless showed lower net income, EPS and adjusted EBITDA, nearly flat free cash flow, higher stock compensation and tax rates, trough-level net revenue retention, and a risk of delayed AI Search revenue.

Bullish
  • + FY27 revenue guidance was raised to $678 million-$683 million, implying 6% growth at the midpoint. new
  • + Workflow usage reached more than half of U.S. prescribers and grew 34% year over year. new
  • + Cost of revenue grew at less than half the rate of overall prompt volume in Q2, indicating improved AI infrastructure efficiency. new
Bearish
  • − Adjusted EBITDA fell 12% year over year and margin contracted to 50.9% from 59.8%. new
  • − Free cash flow was nearly flat year over year and operating cash flow declined 1%.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +32%
above
Price vs 50-day avg +12%
above
RSI (14) 58
neutral
MACD trend Negative
52-week position 46%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +8%
trailing
6-month return +71%
trailing
YTD return −25%
this year
Relative strength +70%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $30 › 200d $25 — 50d above 200d
Institutional flow Distributing
370 of 366 funds reported for Sep 30 · net -7.4M sh shares · +81 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.89% of shares out · ▼ -23.5% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
366 holders — mid 3-yr range
Squeeze score 54
elevated · 0–100
Fundamentals
Strong
Revenue growth +13%
Y/Y
Gross margin 89%
contracting
EPS growth −12%
Y/Y
Free cash flow $326.5M
Valuation P/E 47
in line
Buyback $346.7M
remaining
Quant / Vol
risk profile
Very High
Volatility 63%
annualized · 1-yr
Max drawdown −65%
past year
ATR 4.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the Earnings Call filed Aug 6, 2026
Revenue · fiscal 27 Raised $671M – $681M
May 13, 2026 $664M – $676M changed to Aug 6, 2026 $671M – $681M
prior FY $644.86M midpoint +4.8% Y/Y
Adjusted EBITDA · fiscal 27 Non-GAAP Lowered $309M – $329M
May 13, 2026 $323M – $335M changed to Aug 6, 2026 $309M – $329M
Prior guidance period ended · from the Earnings Call filed Aug 6, 2026
Revenue · Q2-27 $170M – $171M
Adjusted EBITDA · Q2 27 $80.5M – $81.5M
Guided vs delivered · last 8 settled
Revenue Q2-27
guided $170M – $171M
$174.54M Beat +2.4%
Revenue fiscal first quarter ending June 30, 2026
guided $151M – $152M
$156.62M Beat +3.4%
Revenue fiscal fourth quarter ending March 31, 2026
guided $143M – $144M
$145.37M Beat +1.3%
Revenue fiscal year ending March 31, 2026
guided $642.5M – $643.5M
$644.86M Beat +0.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+32% Bullish
Price vs 50-day avg
+12% Bullish
RSI (14)
58 Neutral
MACD trend
Negative Bearish
52-week position
46% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $30 › 200d $25 — 50d above 200d
Institutional flow Distributing
370 of 366 funds reported for Sep 30 · net -7.4M sh shares · +81 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.89% of shares out · ▼ -23.5% MoM · 2.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
366 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $18 Now $33 · 46% Range high $52
vs 200-day avg +32% vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $74.8M fiscal 2027 first quarter —
Adjusted EBITDA margin non-GAAP 47.7% fiscal 2027 first quarter —
Free cash flow non-GAAP $39.6M fiscal 2027 first quarter —
GAAP → non-GAAP reconciliation
GAAP Net cash provided by operating activities 41.99M
-62K Purchases of property and equipment
-2.32M Internal-use software development costs
= Free cash flow 39.6M

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
DOCS
Doximity, Inc.
this stock
$5.95B -24.7% +13.1% 47.0 3.9%
VEEV
Veeva Systems Inc
$48.82B +35.1% +28.1% 49.4 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$14.17B +90.1% +28.2% 38.7 5.8%
TEM
Tempus AI, Inc.
$13.06B +21.3% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
402
% held
67.4%
Reported
370 of 366
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
346
View
Short & Settlement
Short Interest Falling
Shares short
6.9M
Days to cover
2.7d
Change
-2.1M sh
View
Short Volume
Short vol %
50%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
500
Value
$15.5K
As of
Oct 19, 2026
View
Off-Exchange
Off-exchange %
39.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Jonathan Jackson
Amount
$15.0K–$50.0K
Traded
Nov 6, 2025
View
Financials
Financials
Revenue (FY)
$644.9M
Net income (FY)
$196.1M
EPS diluted
$0.98
View
Buybacks
Authorized
$500.0M
Remaining
$346.7M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
13

Doximity reported fiscal 2027 second-quarter revenue of $174.5 million, up 4% year-over-year, while net income fell to $34.7 million. It expects fiscal 2027 revenue of $678 million to $683 million.

View
Proposed Sales
Value
$375.2K
Shares
10.7K
Filed
Nov 5, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Doximity to Provide New Clinical…
Published
Nov 13, 2026
View

Performance

5D 20D 120D MTD YTD
DOCS +2.6% +7.7% +70.8% +1.8% -24.7%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY 0.0% +8.8% +70.3% +2.0% -35.3%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$500.00M
Spent (derived)
$153.30M
Remaining
$346.70M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1516513 CUSIP 26622P107 13F (30d) 340 filings 296 filers Visit website Investor relations